By: Luke Taylor
A vaccine being offered in England to reduce gonorrhoea rates did not cut infections among gay and bisexual men at very high risk of the disease, a randomised controlled trial in Australia suggests.1Since August 2025 health authorities in England have offered the 4CMenB (Bexsero) vaccine to people at high risk of the disease. The new study’s findings are a blow for this, the world’s first national gonorrhoea vaccination programme.The Australian GoGoVax trial, the results of which are published in The New England Journal of Medicine , analysed 587 participants, with roughly half receiving the vaccine and half a placebo.It found no significant difference in the number of infections recorded in the two groups.The authors said the findings provided “strong evidence that the 4CMenB vaccine is not effective for gonorrhoea prevention” among men who have sex with men at high …












